RxDoctor Payments Data

Katy Tsai, MD

Internal Medicine · San Francisco, CANPI 1417275827

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $11,489 of the $12,311 with a category attached, or 93.3%. E.r. Squibb & Sons, L.L.C. accounts for 73.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $5,023 and has fallen 55.8% since, to $2,220 in 2025. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,311in general payments, 2019–2025

Across 19 payments — averaging $647.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$9K
  • Regeneron$2K
  • Sanofi$651
  • Immunocore Limited$146
  • Novartis$122
  • Genentech, Inc.$99
  • plus $97 from 1 others
$3,787,509in research payments, 2019–2025

Across 153 payments — averaging $24,755 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$1.2M
  • Merck$1.1M
  • Array Biopharma Inc$834K
  • Astrazeneca UK Limited$275K
  • Genentech, Inc.$269K
  • Regeneron$57K
  • plus $61K from 2 others

What the payments were for

  • Consulting fees$11,48993%
  • Food & beverage$8227%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,311 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$69,366
Medicare patients
170
Services billed
591

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisone11$98

Paid to pharmacies, not to this prescriber.

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →